WallStSmart

Barrick Mining Corporation (B)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 273% more annual revenue ($63.32B vs $16.96B). B leads profitability with a 29.4% profit margin vs 11.8%. B appears more attractively valued with a PEG of 2.04. B earns a higher WallStSmart Score of 78/100 (B+).

B

Strong Buy

78

out of 100

Grade: B+

Growth: 9.3Profit: 9.0Value: 7.3Quality: 8.5
Piotroski: 7/9Altman Z: 2.38

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 5.3Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BUndervalued (+84.9%)

Margin of Safety

+84.9%

Fair Value

$316.39

Current Price

$43.13

$273.26 discount

UndervaluedFair: $316.39Overvalued
PFEUndervalued (+29.4%)

Margin of Safety

+29.4%

Fair Value

$37.48

Current Price

$25.68

$11.80 discount

UndervaluedFair: $37.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

B6 strengths · Avg: 9.5/10
Operating MarginProfitability
52.6%10/10

Strong operational efficiency at 52.6%

Revenue GrowthGrowth
64.5%10/10

Revenue surging 64.5% year-over-year

EPS GrowthGrowth
150.0%10/10

Earnings expanding 150.0% YoY

Market CapQuality
$70.27B9/10

Large-cap with strong market position

Return on EquityProfitability
20.7%9/10

Every $100 of equity generates 21 in profit

Profit MarginProfitability
29.4%9/10

Keeps 29 of every $100 in revenue as profit

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$150.92B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

B1 concerns · Avg: 4.0/10
PEG RatioValuation
2.044/10

Expensive relative to growth rate

PFE3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : B

The strongest argument for B centers on Operating Margin, Revenue Growth, EPS Growth. Profitability is solid with margins at 29.4% and operating margin at 52.6%. Revenue growth of 64.5% demonstrates continued momentum.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : B

The primary concerns for B are PEG Ratio.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

B profiles as a growth stock while PFE is a value play — different risk/reward profiles.

B carries more volatility with a beta of 1.07 — expect wider price swings.

B is growing revenue faster at 64.5% — sustainability is the question.

PFE generates stronger free cash flow (2.2B), providing more financial flexibility.

Bottom Line

B scores higher overall (78/100 vs 55/100), backed by strong 29.4% margins and 64.5% revenue growth. PFE offers better value entry with a 29.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Barrick Mining Corporation

BASIC MATERIALS · GOLD · USA

Barnes Group Inc. provides engineering products, industrial technologies, and solutions in the United States and internationally. The company is headquartered in Bristol, Connecticut.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?